Compassion, integrity and efficiency are at the center of everything we do to impact the lives of people living with rare cancers. At Ayala, we are dedicated to developing targeted therapies specifically for patients living with rare and aggressive diseases. In combination with next-generation sequencing and our proprietary bioinformatics platform, we are pioneering a novel approach to cancer treatment.
People living with rare and aggressive cancers have an enormous unmet need. We are working to bring a new treatment option to market that can make a true difference in the lives of these individuals and their families. We develop gamma secretase inhibitors to treat cancer. Put in simple terms, it's a way to disrupt tumor growth and metastatic spread by targeting the activation of the Notch pathway.
People living with rare and aggressive cancers have an enormous unmet need. We are working to bring a new treatment option to market that can make a true difference in the lives of these individuals and their families. We develop gamma secretase inhibitors to treat cancer. Put in simple terms, it's a way to disrupt tumor growth and metastatic spread by targeting the activation of the Notch pathway.
Services
Ayala is led by established biotech leaders with proven experience in building and operating R&D organizations, particularly in oncology and rare diseases. Outside of our management team, we are proud to have a committed Board of Directors and group of Advisors.
Our Board of Directors is made up of distinguished industry members including renowned scientists, oncologists, and professors at leading institutions, with extensive healthcare experience to help make key decisions that drive our company forward.Our trusted advisors come from leading medical institutions.
Our Board of Directors is made up of distinguished industry members including renowned scientists, oncologists, and professors at leading institutions, with extensive healthcare experience to help make key decisions that drive our company forward.Our trusted advisors come from leading medical institutions.
Our targeted approach focuses on indications where Notch-pathway activation is a known tumorigenic driver. Using our deep understanding of the Notch pathway, we are developing targeted therapies to address the underlying key drivers of tumor growth in patients where GSI inhibition of Notch may lead to clinical benefit.
At our core, Ayala Pharmaceuticals is founded on our dedication to developing treatments to address the unmet needs of patients living with rare and aggressive cancers. We're always on the lookout to grow our team with people who are collaborative, self-starting, and can thrive in a global team environment with a small biotech company culture.
At Ayala, our work maps back to one underlying goal: Develop and commercialize therapies that improve treatment outcomes for people living with aggressive cancers. By building a pipeline of gamma secretase inhibitors (GSIs) with broad yet targeted clinical utility, we aim to serve patient populations in need of better cancer therapies.
Notch pathway has been implicated in multiple solid tumor and hematological cancers, and often has been associated with aggressive cancers. Notch receptors serve as critical facilitators in processes such as cellular proliferation, survival, migration, invasion, drug resistance and metastatic spread, which all contribute to a poorer prognosis.
Reviews
Be the first to review Ayala Pharmaceuticals.
Write a Review
